Search the Newsreel

Revolution Medicines, Inc. (RVMDW) Stock Price, News, Quote & History

Prime Medicine (NASDAQ:PRME) Trading Up 7.3% - Still a Buy?

BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia

BeOne Medicines and Revolution Medicines have formed a two-part partnership concerning RAS(ON) inhibitors in select Asian markets. The agreement includes clinical combination studies and regional commercialization rights for Revolution Medicines' four clinical-stage RAS(ON) inhibitors. BeOne will also fund and conduct a global registrational Phase …

Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN

Editas Medicine, Inc. reported a net loss of $18.2M and revenues of $11.9M for Q2 2026, with cash reserves sufficient until H2 2028. The company is advancing its EDIT-401 program by filing an Australian CTN to initiate a Phase 1/2 trial for HeFH in …

Cinemark Holdings Inc Cinemark (CNK) Stock Forecasts

Argus has raised its target price for Cinemark Holdings Inc (CNK) to $40.00, with the company currently trading at $37.73. Cinemark is described as a geographically diverse operator in the motion picture exhibition industry in the United States. The report suggests accessing premium research …

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies

BeOne Medicines and Revolution Medicines have announced a collaboration to advance targeted therapies for RAS-addicted cancers. This partnership includes both clinical development of new treatment combinations and a regional commercialization agreement in Asia. The companies aim to explore combinations of BeOne's oncology candidates with …

Scinai Names Eran Kuratz to Lead CDMO Supply Chain and Business Processes

Scinai Immunotherapeutics Ltd. has appointed Eran Kuratz as the head of supply chain and business process administration for its Scinai Biopharma Services subsidiary. This strategic move aims to strengthen operational leadership and integrate the company's expanded contract development and manufacturing organization (CDMO) across its …

Berenberg ajuste ses prévisions pour Gecina après les résultats du premier semestre ; recommandation d'achat maintenue

National CineMedia, Inc. to Release Second Quarter 2026 Results on August 11, 2026

National CineMedia, Inc. (NCM) is scheduled to release its second-quarter 2026 financial results on August 11, 2026. The company will also host a conference call and webcast on the same day to discuss the results and provide a business update. Interested parties can access …

Weekly Recap: Cinemark (CNK) cup-base breakout and record domestic box‑office weekend

Cinemark (CNK) is positioned near a 36.38 cup-base buy point, indicating a potential 34% upside to around $51 by early 2027. This projection is supported by the company's recent record-breaking domestic box office weekend, driven by strong sales from "Spider-Man: Brand New Day" and …

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Scinai Immunotherapeutics has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration for its CDMO subsidiary, Scinai Biopharma Services. This appointment aims to strengthen operational infrastructure and support the integration and scaling of Scinai's expanded CDMO platform, which now includes two …

Price to earnings forward of Cinevista Ltd. – NSE:CINEVISTA

Hua Medicine Sets August Board Meeting to Approve Interim Results

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines and Revolution Medicines have announced a multi-part collaboration focusing on clinical development and regional commercialization. The collaboration includes evaluating drug combinations of BeOne's oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors for RAS-addicted cancers, and a regional rights agreement granting BeOne …

Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?

Parabilis Medicines (Nasdaq:PBLS) - Stock Analysis

Parabilis Medicines (PBLS) is a clinical-stage biopharmaceutical company with a market cap of US$4.6 billion. The company recently completed a record-breaking biotech IPO, raising substantial capital to fund a pivotal Phase 3 cancer therapy trial and expand its Helicon platform. Despite significant capital raises …

The Manufacturers Life Insurance Company Decreases Stock Position in Disc Medicine, Inc. $IRON

The Manufacturers Life Insurance Company reduced its stake in Disc Medicine, Inc. by 38.1% in the first quarter, selling 20,017 shares and retaining 32,493 shares valued at approximately $2.1 million. This comes amidst significant insider selling, including by CEO John D. Quisel, and an …

Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME

Renaissance Technologies LLC has reduced its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 35.5%, selling 408,120 shares but still retaining 741,039 shares valued at approximately $2.58 million. This comes as Prime Medicine reported a quarterly loss of $0.24 per share, meeting analyst estimates, yet …

Cintas Earns Place on U.S. News & World Report’s List of 2026-2027 Best Companies to Work For

Cintas Corporation has been recognized by U.S. News & World Report as one of the 2026-2027 Best Companies to Work For, marking its second consecutive year receiving this honor. The recognition is based on an evaluation of 3,900 organizations across various categories, with Cintas …

Disc Medicine, Inc. $IRON Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its stake in Disc Medicine, Inc. by 29.7% in the second quarter, selling 162,089 shares and retaining 384,158 shares valued at $28.1 million. Despite insider sales totaling nearly $8.0 million and an ongoing investigation by Rosen Law Firm, analysts …

Cincinnati Financial Corp (CINF) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cincinnati Financial Corp (CINF), highlighting its current earnings forecast score of 7.00 and an average analyst price target of $174.50. Based on 10 analysts, the stock receives a "Hold" rating. Key financial metrics such as expected quarterly …

Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

HC Wainwright Decreases Earnings Estimates for Disc Medicine

HC Wainwright has lowered its Q3 2026 earnings estimate for Disc Medicine (NASDAQ:IRON) to a loss of $1.71 per share, from a previous forecast of $1.70, while maintaining a "Buy" rating and a $120 price target. Despite the lowered estimates, the company recently reported …

Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history

This page provides a comprehensive overview of Praxis Precision Medicines, Inc. (PRAX) stock, including its current price, historical data, key statistics, and company profile. It details the company's focus on developing therapies for CNS disorders and lists its pipeline of clinical-stage and preclinical drug …

Cineverse Corp (CNVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cineverse Corp (CNVS), detailing its current earnings forecast score, analyst ratings, and price targets. Based on two analysts, the stock has an average price target of $7.50, with a "Buy" trend. The expected revenue for the next …

Trading the Move, Not the Narrative: (CNK) Edition

This article provides an AI-generated analysis for Cinemark Holdings Inc. (NYSE: CNK), indicating a strong overweight bias across all horizons. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders on potential entry, target, and …

How nCino’s New MCP-Powered Mortgage AI Layer Could Impact nCino (NCNO) Investors

nCino recently launched Mortgage MCP, an AI-powered solution that integrates AI agents directly into its Mortgage Suite, aiming to automate administrative and loan officer tasks through natural language. This development could reshape nCino's investment narrative by reinforcing its AI-driven workflow automation, potentially leading to …

Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances

Praxis Precision Medicines (PRAX) has achieved a significant milestone with its investigational treatment Elsunersen receiving FDA Breakthrough Therapy designation, advancing its central nervous system pipeline. Despite this regulatory success and other late-stage assets, the company reported substantial net losses and no meaningful revenue in …

Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD

Assenagon Asset Management S.A. recently acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD), purchasing 200,486 shares valued at approximately $37.55 million in the second quarter. This move makes Assenagon Asset Management S.A. the owner of 0.09% of Revolution Medicines' stock. Other institutional investors …

Previsioni su azioni Unipol Assicurazioni, Officina Stellare, Technoprobe

Disc Medicine Inc (IRON) Earnings Forecast: Future EPS & Revenue Growth Estimates

nCino (NCNO) Launches Mortgage MCP As Its Undervalued Narrative Faces A Fresh Test

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Mortgage MCP launch reframes the nCino (NCNO) story for investors nCino (NCNO) has rolled out Mortgage MCP, a new set of AI agent connections for …

Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen has downgraded Generate Biomedicines (NASDAQ:GENB) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly loss of $0.52 per share, missing estimates, and generated $6.31 million in revenue. Institutional activity includes …

Price to earnings forward of New Ray Medicine International Holding Ltd. – HKEX:6108

We Might See A Profit From Everest Medicines Limited (HKG:1952) Soon